Permanent Indian Bar Against Glenmark’s Sitagliptin Copies

An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.

More from India

More from Focus On Asia